Last reviewed: June 21, 2026

Last updated: June 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide's journey to weight loss approval marked a turning point in obesity treatment. In November 2021, the FDA approved semaglutide (marketed as Wegovy) for chronic weight management in adults with obesity or overweight status plus weight-related conditions. This milestone followed over a decade of research demonstrating the medication's ability to help patients lose up to 15% of their body weight.

FDA Approval History for Semaglutide Weight Loss

Semaglutide was first approved by the FDA in 2017 for type 2 diabetes management under the brand name Ozempic. The injectable medication had already demonstrated significant metabolic benefits in diabetic patients. Researchers noticed a consistent side effect: meaningful weight reduction in study participants. This observation led to dedicated obesity trials and eventually a separate weight loss indication.

The STEP trials (Semaglutide Treatment Effect in People with obesity) enrolled over 4,500 participants across four randomized, double-blind studies. Results showed semaglutide 2.4 mg weekly produced an average 12-22% weight loss over 68 weeks, substantially outperforming previous non-surgical weight management options. The FDA's November 2021 decision formally recognized semaglutide's efficacy for chronic weight management in non-diabetic populations.

How Semaglutide Works for Weight Loss

Semaglutide mimics glucagon-like peptide-1 (GLP-1), a natural hormone that regulates appetite and blood sugar. The medication activates GLP-1 receptors in the brain's appetite centers, reducing hunger signals and increasing feelings of fullness. This mechanism differs from stimulant-based weight loss drugs, offering a more physiologic approach to sustained weight reduction.

Beyond appetite suppression, semaglutide slows stomach emptying and improves insulin sensitivity. These combined effects help patients achieve caloric deficit more naturally while maintaining metabolic rate. Clinical data shows benefits extend beyond weight loss alone—improvements in cardiovascular markers, blood pressure, and inflammatory biomarkers occur in most patients treated for 12+ months.

Compounded Semaglutide vs. Brand-Name Options

While Wegovy remains the FDA-approved brand, PlexusDx offers compounded semaglutide injections from licensed 503A compounding pharmacies at more accessible price points. Compounded medications contain identical active pharmaceutical ingredients but are prepared by certified pharmacists rather than manufactured in mass-production facilities. The compounding process maintains the same purity, potency, and safety standards required for prescription medications.

PlexusDx compounded semaglutide injections start at $149 per month with no insurance requirement, no membership fees, and HSA/FSA eligibility. Patients maintain flexibility to adjust doses based on tolerance and results, with pricing remaining flat regardless of dose escalation. This structure contrasts with retail pharmacy options where brand-name medications often carry higher out-of-pocket costs and insurance barriers.

Personalized Treatment with Genetic Testing

Individual responses to semaglutide vary significantly based on genetic predispositions affecting GLP-1 receptor sensitivity, appetite regulation, and fat metabolism. PlexusDx offers the Precision Peptide Genetic Test, a peptide-pathway analysis examining key variants including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. These insights reveal which patients are likely responders versus those who may benefit from combination therapy or alternative compounds.

The genetic test maps 14 metabolic pathways and 150+ specific insights, allowing clinicians to predict semaglutide efficacy before starting treatment. Patients with favorable GLP1R variants often achieve results comparable to clinical trials, while those with certain FTO variants may require higher doses or dual-compound approaches. This precision-medicine approach optimizes outcomes and reduces trial-and-error treatment cycles.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the difference between Ozempic and Wegovy?

Ozempic and Wegovy contain identical semaglutide but differ in FDA-approved indications and marketing. Ozempic targets type 2 diabetes, while Wegovy targets chronic weight management. Both use the same active compound; the approval distinction reflects separate clinical trial programs. PlexusDx compounded semaglutide provides the same mechanism for weight loss at lower cost.

How much weight do patients typically lose with semaglutide?

STEP trial data demonstrated average weight loss of 12-22% over 68 weeks at the 2.4 mg maintenance dose, with some patients exceeding 20% reductions. Individual results depend on baseline weight, dose tolerance, adherence, lifestyle factors, and genetic predispositions. PlexusDx patients who complete the Precision Peptide Genetic Test receive personalized efficacy predictions based on their GLP-1 pathway genetics.

How much does PlexusDx semaglutide cost compared to brand-name Wegovy?

PlexusDx compounded semaglutide injections start at $149 per month, with pricing remaining flat regardless of dose escalation. Brand-name Wegovy typically costs $900-$1,350 monthly out-of-pocket without insurance. PlexusDx serves all 50 states, requires no insurance, and accepts HSA/FSA payments, making treatment accessible to a broader patient population.

Are there side effects with semaglutide for weight loss?

Common side effects include mild nausea, vomiting, constipation, and diarrhea, typically resolving within weeks as patients acclimate. Serious side effects are rare but include pancreatitis and gallbladder complications in susceptible individuals. PlexusDx clinicians screen for contraindications and monitor patients during dose titration, with most tolerating the medication well at gradual escalation schedules.

Can genetic testing predict if semaglutide will work for me?

PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R variants to estimate treatment response likelihood. Patients with favorable GLP1R genetics typically show robust weight loss comparable to STEP trials, while specific FTO variants predict need for combination therapy. This test costs $99 as an add-on after the first month of treatment and guides personalized protocol selection.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves